ORPHA:494547
Squamous cell carcinoma of the hypopharynx
Publications
3,721
91.1th percentile
Trials
120
Interventional, condition-specific
Researchers
977
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare head and neck tumor characterized by a malignant epithelial neoplasm with evidence of squamous differentiation, most commonly located in the piriform sinus, less frequently the posterior pharyngeal wall or the postcricoid area. The tumor can spread directly to adjacent structures or metastasize via lymphatic and blood vessels to regional lymph nodes, or lung, liver, and bones, respectively. Primary risk factors are tobacco smoking and (to a lesser extent) alcohol consumption. Patients may present with odynophagia, dysphagia, signs and symptoms related to a neck mass, voice changes, otalgia, and constitutional symptoms.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0044638
- UMLS:C0280321
- NCIT:C4043
Additional Mondo synonyms (6)
epidermoid carcinoma of hypopharynx · epidermoid carcinoma of the hypopharynx · hypopharyngeal epidermoid carcinoma · hypopharyngeal squamous cell carcinoma · hypopharyngeal throat squamous cell cancer · squamous cell carcinoma of hypopharynx
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,721 matched papers (2,387 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
120 matched on ClinicalTrials.gov (22 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
24
Drugs / clinical candidates · MONDO_0044638
- AVELUMAB·phase 3
- CAPECITABINE·phase 3
- CETUXIMAB·phase 3
- CISPLATIN·phase 3
- FLUOROURACIL·phase 3
- METHOTREXATE·phase 3
- PACLITAXEL·phase 3
- PANITUMUMAB·phase 3
- TISLELIZUMAB·phase 3
- TRETINOIN·phase 3
- VINFLUNINE·phase 3
- CARBOPLATIN·phase 2
- CONTUSUGENE LADENOVEC·phase 2
- DOCETAXEL·phase 2
- NIMOTUZUMAB·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,721
3,721 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,721 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,387 in the last 10 years · high confidence · 91.1th percentile (publications denominator)
Phrase hits: 3,721 · MeSH hits: 0
Who's working on it?
977
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang Y12 papers · 2026
Department of Otolaryngology, Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Papers in Europe PMC - 02Wang J11 papers · 2026
Division of Applied Oral Sciences & Community Dental Care, Faculty of Dentistry, the University of Hong Kong, Hong Kong SAR, China. Junwen@hku.hk.
Papers in Europe PMC - 03Tao L10 papers · 2026
ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Papers in Europe PMC - 04Wang X9 papers · 2026
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Papers in Europe PMC - 05Chen Y8 papers · 2026
Country Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Papers in Europe PMC - 06Li Z8 papers · 2026
Institute for Viral Hepatitis & Department of Infectious Diseases, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Papers in Europe PMC - 07Liu Z8 papers · 2026
Department of Head and Neck Radiotherapy, Shandong Provincial ENT Hospital, Shandong University, Jinan, China.
Papers in Europe PMC - 08Zhang X8 papers · 2026
Department of Otolaryngology, the Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Papers in Europe PMC - 09Chen X7 papers · 2026
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Papers in Europe PMC - 10Liu S7 papers · 2026
Department of Head Neck and Thyroid Surgery, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
120
interventional trials for this specific condition
120 interventional trials matched this specific condition name; 22 currently recruiting in our sample.
Data as of 11 September 2026
120 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.7th percentile).
high confidence · 98.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
120 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05136196·RECRUITING·BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Not reviewed·Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8·Matched via name phrase
- NCT07423078·RECRUITING·Window of Opportunity in Preserving Laryngeal Function Trial
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) · Locally Advanced Laryngeal Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT06137378·RECRUITING·European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
Not reviewed·Conditions: Squamous Cell Carcinoma of Head and Neck · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma Stage III · Laryngeal Squamous Cell Carcinoma Stage IV·Matched via name phrase
- NCT06636734·RECRUITING·Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary · Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Hypopharyngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT06980038·RECRUITING·Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma · Nasal Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT05172245·RECRUITING·Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Carcinoma of Unknown Primary · Locally Advanced Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06532279·RECRUITING·Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06894459·NOT YET RECRUITING·A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Cancers·Matched via name phrase
- NCT06589804·RECRUITING·Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Not reviewed·Conditions: Metastatic Head and Neck Squamous Cell Carcinoma · Metastatic Hypopharyngeal Squamous Cell Carcinoma · Metastatic Laryngeal Squamous Cell Carcinoma · Metastatic Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
- NCT01473784·RECRUITING·Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Not reviewed·Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity · Recurrent Mucoepidermoid Carcinoma of the Oral Cavity · Recurrent Squamous Cell Carcinoma of the Hypopharynx · Recurrent Squamous Cell Carcinoma of the Larynx·Matched via name phrase
- NCT07156227·RECRUITING·Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05752149·NOT YET RECRUITING·Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial
Not reviewed·Conditions: Squamous Cell Carcinoma of the Larynx · Squamous Cell Carcinoma of the Hypopharynx·Matched via name phrase
- NCT06914999·RECRUITING·Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Not reviewed·Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07665190·RECRUITING·Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Not reviewed·Conditions: Hypopharyngeal Squamous Cell Carcinoma·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06380686·RECRUITING·Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Not reviewed·Conditions: Squamous Cell Carcinoma of the Oral Cavity · Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Hypopharynx · Squamous Cell Carcinoma of the Larynx·Matched via name phrase
- NCT06947668·RECRUITING·Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Not reviewed·Conditions: Squamous Cell Carcinoma of Oropharynx · Squamous Cell Carcinoma of the Hypopharynx · Larynx Squamous Cell Carcinoma · Oral Cavity Squamous Cell Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 28 · after dedupe 28 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 28 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (28)
- ctis·2024-520264-33-00·Authorised, ongoing·Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD-L1 positive HNSCC (CPS≥1)
skipped — LLM skipped (--skip-llm)
- ctis·2024-516536-10-00·Expired·Combined Pembrolizumab and Lenvatinib after definitive Chemoradiation of locally advanced HNSCC
in PD-L1 positive patients (CPS≥1)
skipped — LLM skipped (--skip-llm)
- ctis·2024-511477-29-00·Authorised, recruiting·AFAN trial. Phase Ib/II study to investigate the safety and efficacy of Afatinib when administered as therapy in Fanconi anemia patients with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15819396·Recruiting·A Phase I/IIa trial of KJ-103 in solid cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11188227·Recruiting·Prophylactic swallowing exercise protocol in head and neck cancer patients: combination of self-directed and supervised training
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11941599·Recruiting·JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab in LA-HNSCC
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14471479·Recruiting·How mouth bacteria affect radiation treatment for head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14681287·No longer recruiting·Can we use ultrasound to assess the structure and size of important speech and swallowing muscles before and after radiotherapy ?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98745687·No longer recruiting·A Phase Ib/II, open-label study of amivantamab monotherapy and amivantamab in addition to other therapeutic agents in participants with head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63646763·No longer recruiting·A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66274524·No longer recruiting·Accelerating the development and implementation of DNA damage inhibitor and radiotherapy treatment (with or without immunotherapy) in head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN93840508·Stopped·Hyperbaric radiation sensitization of head and neck cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89314418·Stopped·Cetuximab immunotherapy combination in head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14224600·No longer recruiting·LiTEFORM light therapy effectiveness for oral mucositis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76291951·No longer recruiting·WISTERIA: WEE1 inhibitor with cisplatin and radiotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN25458988·No longer recruiting·A study examining whether a new radiotherapy technique (“dysphagia optimised intensity modulated radiotherapy”) will improve swallowing function after treatment in head and neck cancer patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44435485·No longer recruiting·Accelerated hypofractionation, Chemotherapy, Intensity Modulation and Evaluation of Dose Escalation in Oropharyngeal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN87302591·No longer recruiting·Effect of a topical treatment on skin when having chemotherapy and radiotherapy to the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74465582·No longer recruiting·Trial of Induction TPF therapy in Advanced head & Neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN87356938·No longer recruiting·Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux® And CHemotherapy for unresectable carcinomas of head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52466525·No longer recruiting·Phase III trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12244200·No longer recruiting·A phase I clinical trial of Hyperbaric Oxygen combined with radiation and chemotherapy for locally advanced squamous cell carcinoma of the head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47339346·No longer recruiting·Phase I-/II-study of Hyperfractionated-Accelerated Radiation Therapy plus Cetuximab plus Cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72086307·No longer recruiting·Post-OPerative Accelerated RadioTherapy versus conventional radiotherapy in squamous cell head and neck cancer: a phase III randomised study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN06768231·No longer recruiting·The effect of comprehensive counseling by a nurse specialist on depressive symptoms and quality of life: a prospective randomised study in patients with head and neck cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the hypopharynx — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the hypopharynx" OR "Squamous cell carcinoma of hypopharynx" OR "epidermoid carcinoma of hypopharynx" OR "epidermoid carcinoma of the hypopharynx" OR "hypopharyngeal epidermoid carcinoma" OR "hypopharyngeal squamous cell carcinoma" OR "hypopharyngeal throat squamous cell cancer"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the hypopharynx" OR "Squamous cell carcinoma of hypopharynx" OR "epidermoid carcinoma of hypopharynx" OR "epidermoid carcinoma of the hypopharynx" OR "hypopharyngeal epidermoid carcinoma" OR "hypopharyngeal squamous cell carcinoma" OR "hypopharyngeal throat squamous cell cancer"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 120 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T17:33:13.948Z
